AI is reshaping pharma pricing & market access - but are you capturing real impact or just running pilots? Join our experts on June 11 to explore how leading teams are scaling AI across evidence generation, launch planning, and value communication. Register here: skp.link/udyl #BetterGrowthwithAI #AIinPharma #AI #Pricing #MarketAccess
Info
Simon-Kucher is a global consultancy with more than 2,200 employees in 30+ countries. As a trusted commercial advisor focused on unlocking better growth, we combine deep consulting expertise, growth specialization, and technology to scale lasting impact. We optimize every lever of commercial strategy – product, pricing, innovation, marketing, and sales – based on what customers want and value. With over 40 years of monetization experience, we are recognized as the world’s leading commercial growth and pricing specialist. (Legal notice: https://www.simon-kucher.com/en/legal-notice) -- Terms of use: Simon-Kucher's official LinkedIn page is run by Simon-Kucher & Partners Strategy & Marketing Consultants (SK). This is a public forum and we welcome your comments, thoughts and insights. However, all posts are regularly monitored and SK will remove, hide and/or delete any that are found to be abusive or deemed inappropriate for this page for whatever reason, including content that is deemed none compliant with LinkedIn’s User Agreement (https://www.linkedin.com/legal/user-agreement). This includes the banning and reporting of users who are deemed to be non compliant with the above expectations of Simon-Kucher. All comments, visuals, links to other digital pages and other type of material posted by followers on this site ("User Content") do not necessarily reflect the opinions or values of SK, its employees, partners or affiliates. SK does not represent or warrant the accuracy of any statement or product claims made here, is not responsible for any User Content on this site and does not endorse any opinions expressed on this page.
- Website
-
https://www.simon-kucher.com
Externer Link zu Simon-Kucher
- Branche
- Unternehmensberatung
- Größe
- 1.001–5.000 Beschäftigte
- Hauptsitz
- Bonn
- Art
- Privatunternehmen
- Spezialgebiete
- Strategy, Marketing, Pricing, Sales und Digital
Orte
Beschäftigte von Simon-Kucher
Updates
-
Disruption is an inevitability for businesses. The real question is whether firms have built the capability to harness disruption as an advantage. Ultimately, volatility rewards firms that are prepared. Higher costs are coming and if businesses don’t act, they will erode margins. Adam Echter’s latest article in Chief Executive Group magazine underscores three scenarios for turning challenges into fresh growth opportunities. Read the full article here to learn how to grow in volatility: skp.link/8jz3 #BusinessGrowth #Volatility #PricingStrategy #CommercialExcellence #Simon-Kucher
-
-
50% of manufacturers and labs plan to implement Clinical Decision Support (CDS) within the next two to three years. Yet as CDS becomes a portfolio priority in diagnostics, the real question is where it truly creates value. Manufacturers and labs that aim to lead must approach CDS investment with discipline. Our latest blog explores adoption trends, commercialization barriers, and how manufacturers can decide whether to build, buy, partner, or step back: skp.link/clkq #LabOfTheFuture #ClinicalDecisionSupport #Diagnostics #Strategy #CDS
-
-
Celebrating 25 years in Tokyo! From its entrepreneurial beginnings in 2001 to a strong and steadily growing presence today, our Tokyo office has built a unique culture shaped by resilience, ownership, and collaboration. Kaori Yamamoto, Office Manager in Tokyo, shares her perspective on the journey, the people behind it, and what continues to make the office a special place to work. Read more: skp.link/nzrd #SKLife #Tokyo #Anniversary
-
-
The traditional “US-first” launch model in the pharma industry is being challenged. Global launch sequencing today requires navigating evolving HTA expectations, pricing pressures, and increasingly connected international markets. In tomorrow’s webinar, our experts Xirong Song and Christian Schuler together with senior industry leaders explore how pharma and biotech leaders are adapting their strategies to make smarter, more resilient launch decisions in a rapidly changing landscape. Register now! skp.link/i7ts #BetterCommercialGrowth #Pharma #LaunchSequencing #Pricing #IRP
-
-
What happens when launch sequencing starts to shape pricing power? In an MFN landscape, the GENEROUS 8 launch strategy brings that question into sharp focus. Our latest analysis explores the trade-offs that could redefine pharma access, value, and global launch decisions. skp.link/j2s2 #BetterMarketAccess #MFN #GENEROUS #Strategy #USPharma
-
-
Swapping for a good cause! At our Warsaw office, colleagues came together for our Simon-Kucher Network of Women (NoW) charity and integration event, swapping pre-loved clothes and items to give them a second life while supporting “Bezpieczna Przystań” Single Mothers’ Home in Zielonka and the “Betania” shelter for people experiencing housing crisis in Warsaw 💙 A big thank you to the organizers Weronika Warzec, Justyna Marek, Claudia Konarzewski, and Wioleta Chojnacka for making this initiative possible. A great example of how small actions can bring people together and create real impact. #SKLife #GivingBack #NetworkofWomen
-
-
Many AI transformations fall short not because of the tech, but because of the execution. Clear growth strategy, strong data foundations, and real adoption are what turn AI from a pilot into commercial impact. In this video, Simon-Kucher Partner Sara Yamase shares what it takes to make AI a sustainable growth driver. Discover more here: skp.link/jbal #MontizingGenAI #GenAI #AITransformation #GrowthStrategy
-
Customers rarely leave in a dramatic exit. They drift. They open your emails a little less often. Log in less frequently. Ignore the last upgrade prompt. By the time they click “cancel”, the decision has already been made. In this article of The Growth Blueprint we dive into how customer value is lost – and found. Read here: skp.link/iub4 #TheGrowthBlueprint #SKMagazine#CustomerLoyalty #CustomerValue #BehavioralEconomics
-
-
For decades, the semiconductor industry operated with expectations of better performance at a lower cost. However, this expectation is shifting as new technology becomes more expensive, scaling is more difficult, and geopolitical pressures add structural costs. Even as cost-down expectations continue, the economics can no longer support them. The risk now is under-monetizing innovation that enables next-generation computing. To adapt to this shifting environment, chip pricing must be based on system-level value, not cost curves. Read more in our latest blog by Rohit Mathew, Tyler Stutzman, Sandeep George, and Emery Engling: skp.link/hgpe #Pricing #MooresLaw #SemiconductorManufacturing #Innovation #SimonKucher
-